Curcumin and cognition: a randomized, placebo-controlled, double-blind study of community-dwelling older adults

Authors

Stephanie Rainey-Smith, Edith Cowan UniversityFollow
Belinda M. Brown, Edith Cowan UniversityFollow
Hamid R. Sohrabi, Edith Cowan UniversityFollow
Tejal Shah, Edith Cowan UniversityFollow
Kathryn G. Goozee
Veer Gupta, Edith Cowan UniversityFollow
Ralph N. Martins, Edith Cowan UniversityFollow

Document Type

Journal Article

Publisher

Cambridge University Press

School

School of Medical and Health Sciences / Centre of Excellence for Alzheimer’s Disease Research and Care

RAS ID

21242

Comments

Rainey-Smith, S. R., Brown, B. M., Sohrabi, H. R., Shah, T., Goozee, K. G., Gupta, V. B., & Martins, R. N. (2016). Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. British Journal of Nutrition, 115(12), 2106-2113. Available here.

Abstract

Curcumin therapy in animals has produced positive cognitive and behavioural outcomes; results of human trials, however, have been inconsistent. In this study, we report the results of a 12-month, randomised, placebo-controlled, double-blind study that investigated the ability of a curcumin formulation to prevent cognitive decline in a population of community-dwelling older adults. Individuals (n 96) ingested either placebo or 1500 mg/d Biocurcumax^TM for 12 months. A battery of clinical and cognitive measures was administered at baseline and at the 6-month and 12-month follow-up assessments. A significant time×treatment group interaction was observed for the Montreal Cognitive Assessment (repeated-measures analysis; time×treatment; F=3·85, P

DOI

10.1017/S0007114516001203

Access Rights

free_to_read